Dynavax Technologies Co. (NASDAQ:DVAX) Shares Purchased by Comerica Bank

Comerica Bank raised its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 62.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 59,412 shares of the biopharmaceutical company’s stock after purchasing an additional 22,831 shares during the quarter. Comerica Bank’s holdings in Dynavax Technologies were worth $759,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC raised its position in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies during the 4th quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 6th. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research note on Thursday, April 17th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, JMP Securities reduced their target price on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $24.00.

Dynavax Technologies Stock Down 2.3%

DVAX stock opened at $9.62 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.16 billion, a P/E ratio of 53.44 and a beta of 1.26. Dynavax Technologies Co. has a 52-week low of $9.28 and a 52-week high of $14.63. The company’s 50 day simple moving average is $12.16 and its 200-day simple moving average is $12.57.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million for the quarter, compared to analysts’ expectations of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.